drugset / Trial / NCT03675776
Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
RandomizedParallel-groupDouble-blindTreatment
Summary
The study will evaluate the efficacy, safety, and tolerability of 225 milligrams (mg) and 450 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
Timeline
- Start
- 2018-10-30
- Primary completion
- 2019-07-11
- Completion
- 2019-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rapastinel | Other / unclassified | 225 mg | Intravenous |
| Subject | Rapastinel | Other / unclassified | 450 mg | Intravenous |